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Background: Human papillomavirus (HPV) inactivates the retinoblastoma 1 (RB1) gene by promoter methylation
and reduces cellular E-cadherin expression by overexpression of DNA methyltransferase 1 (DNMT1). The Epstein-Barr
virus (EBV) is an oncogenic virus that may be related to cervical carcinogenesis. In gastric cancer, it has been
demonstrated that E-cadherin gene (CDH1) hypermethylation is associated with DNMT1 overexpression by EBV infection.
Our aim was to analyze the gene promoter methylation frequency of RB1 and CDH1 and verify the association
between that methylation frequency and HPV and EBV infection in cervical lesions.
Methods: Sixty-five samples were obtained from cervical specimens: 15 normal cervices, 17 low-grade squamous
intraepithelial lesions (LSIL), 15 high-grade squamous intraepithelial lesions (HSIL), and 18 cervical cancers. HPV and EBV
DNA testing was performed by PCR, and the methylation status was verified by MSP.
Results: HPV frequency was associated with cervical cancer cases (p = 0.005) but not EBV frequency (p = 0.732). Viral
co-infection showed a statistically significant correlation with cancer (p = 0.027). No viral infection was detected in
33.3% (5/15) of controls. RB1 methylated status was associated with cancer (p = 0.009) and HPV infection (p = 0.042).
CDH1 methylation was not associated with cancer (p = 0.181). Controls and LSIL samples did not show simultaneous
methylation, while both genes were methylated in 27.8% (5/18) of cancer samples. In the presence of EBV, CDH1
methylation was present in 27.8% (5/18) of cancer samples. Only cancer cases presented RB1 promoter methylation in
the presence of HPV and EBV (33.3%).
Conclusions: The methylation status of both genes increased with disease progression. With EBV, RB1 methylation was
a tumor-associated event because only the cancer group presented methylated RB1 with HPV infection. HPV
infection was shown to be significantly correlated with cancer conditions. The global methylation frequency was
higher when HPV was present, showing its epigenetic role in cervical carcinogenesis. Nevertheless, EBV seems to be a
cofactor and needs to be further investigated.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1159157579149317.
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Cervical cancer represents an important public health
problem, as it is the fourth most common type of carcin-
oma in women worldwide. This disease was responsible
for 265,000 deaths in 2012, of which 87% occurred in
developing countries [1]. According to the National
Cancer Institute (INCA-Brazil), in general, its mortality/
incidence ratio is 52% [2] and its survival rate is 70% [1].
Genital human papillomavirus (HPV) infection causes
virtually all cervical cancer cases [3], and the factors corre-
lated with development from the initial lesion to invasive
carcinoma are poorly understood [4]. The 40 genotypes of
genital HPVs can be classified as low-risk and high-risk
based on their oncogenic ability [5]. Among the high-risk
HPVs (HR-HPV), HPV16 is of major clinical importance,
causing over 50% of cervical cancer cases [6].
Cervical carcinogenesis is a stepwise process in which
genetic and epigenetic abnormalities are seen in regulatory
genes. Epigenetic alterations may modify the expression
of HPV genes or even host genes, leading to silencing of
tumor suppressor genes (TSGs) by promoter hyperme-
thylation [7].
The E7 HPV oncoprotein is essential for the host cell
transformation and immortalization process [8]. It is
known that this oncoprotein inactivates the retinoblast-
oma 1 (RB1) gene by promoter methylation, which is es-
sential in cervical tumorigenesis in humans [9]. E7 also
has the ability to reduce cellular expression of E-cadherin,
one of the major cell adhesion molecules, by overexpres-
sion of DNA methyltransferase 1 (DNMT1), an enzyme
responsible for maintaining methylation patterns [10].
Thus, the cellular reduction of E-cadherin by gene pro-
moter methylation may indicate a risk of local invasion
and metastasis.
The Epstein-Barr virus (EBV), a member of the human
herpes virus group, has been suggested as another onco-
genic virus related to cervical carcinogenesis, as it is
present in subclinical infection and invasive carcinoma
of the cervix [11]. In gastric cancer, it has been demon-
strated that hypermethylation of CDH1, which expresses
the E-cadherin protein, is associated with DNMT1 over-
expression by EBV infection [12]. However, until now,
this association with cervical carcinogenesis has not
been described.
The relationship between viruses and cancer is well
established. However, the epigenetic pathways that
determine the regression or persistence of infection
and also the progression from precursor lesions to
cancer are not clear. Therefore, our aim was to
analyze the gene promoter methylation frequency of
RB1 and CDH1 and to verify the association between
that methylation frequency and HPV and EBV infec-
tion in cervical lesions as well as in normal cervical
epithelia.Methods
Samples
This transversal study was performed with samples ob-
tained from cervical specimens of 65 women over the
age of 18 who attended the Cervical Pathology Out-
patient Clinic of the Gynecology Institute of the Federal
University of Rio de Janeiro, Brazil, between July 2006
and July 2013, excluding only unavailable samples and/
or those in poor condition. Because of those exclusion
criteria, we worked with 65 samples.
The control samples were obtained from 15 cervical
specimens with normal cytology and colposcopy, and 50
patients showing prior cytology with cervical lesions
were classified by its cytological alterations as follows:
17 low-grade squamous intraepithelial lesions (LSILs),
15 high-grade squamous intraepithelial lesions (HSILs),
and 18 cervical cancers.
Patients showing cytology with a diagnosis of HSIL
or cancer were submitted to guided colposcopy bi-
opsy, and cells were obtained from cervical brushings
from patients with LSIL as well as from the control
group.
The cervical smears and biopsies were taken as part of
a routine screening program for cervical carcinoma. The
cervical smears were collected with cervix brushes in
phosphate-buffered saline, and the biopsies were ob-
tained by cervical conization. All samples were analyzed
in the Pathological Anatomy Laboratory from the same
Gynecology Institute and were reviewed and classified
by a certified pathologist.
This research was approved by ethical review boards
from the Maternity School of the Federal University of
Rio de Janeiro. Patients were asked to participate in the
study, and informed consent was obtained before sample
collection.DNA extraction
The DNA extraction of the biopsy samples and cervical
brushings was performed as described by Lattario et al.
(2008) [13]. Briefly, these samples were digested in 500
μL of solution containing 10 mM Tris-HCl, pH 7.5, 10
mM NaCl, 2% SDS, 10 mM EDTA, pH 8.0, and 15 μL
10 mg/mL proteinase K and incubated for 16 hours at
55°C, followed by phenol-chloroform (1:1) extraction.
The DNA was precipitated using ethanol at -20°C for 16
hours, and then the samples were washed with 80% etha-
nol, re-suspended in 20 μL of water and stored at -20°C
until use.
The DNA was isolated by previous PCR amplification
with exon 5 p53 primers as an internal marker to ensure
that the isolated DNA from samples and the following
PCR were performed correctly, as described by Pestener
et al. (1994) [14].
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HPV and EBV DNA testing was performed using PCR
methods. Detection of HPV was performed with the
MY09 e MY11 [15] consensus primers, which amplify a
450-bp fragment. To detect EBV, we used consensus
primers TC67 and TC69 [16], whose product is 288 bp.
Both amplifications were performed in a thermocycler.
The protocol for HPV detection was as follows: 5 minutes
of initial denaturing at 95°C; 35 cycles at 95°C, at 60°C
and at 72°C for 1 minute at each temperature; and a
final elongation step at 72°C for 10 minutes. The PCR
for EBV detection was performed as follows: 1 minute
of denaturing at 95°C; followed by 40 cycles of 1 minute
at 94°C, 2 minutes at 55°C and 1 minute at 72°C; and a
final elongation of 5 minutes at 72°C. The amplicons
were stored at 4°C until time of use. HeLa and Raji cell
lines were used as positive reaction controls for HPV
and EBV, respectively. Samples containing just the reac-
tion mixture without the template were analyzed as
negative controls.
Bisulfite treatment
The extracted genomic DNA underwent sodium bisulfite
modification as described by Rosas et al. (2001) [17].
This method transforms the unmethylated cytosines into
uracils and does not alter the methylated cytosines.
Briefly, 1 μg of genomic DNA was diluted in 50 μL of
distilled water and denatured in 0.2 M NaOH for 10
min at 37°C. The denatured DNA was then resuspended
in 550 μL of freshly prepared solution containing 10
mM hydroquinone (Sigma, St. Louis, MO) and 3 M so-
dium bisulfite, pH 5.0 (Sigma), and incubated at 50°C.
After 16 hours of incubation, the DNA samples were de-
salinated through a column (Wizard DNA Clean-Up
System, Promega, Madison, WI), treated with 0.3 M
NaOH for 15 min at room temperature and precipitated
with ethanol. The bisulfite-modified genomic DNA was
resuspended in 30 μL of distilled water and immediately
used or stored at -20°C.
PCR amplification of bisulfite-modified DNA
The sodium bisulfite modification was followed by
methylation-specific PCR (MSP method). In this proced-
ure, the treated DNA was used as a template for PCR
amplification using specific primers for RB1 [18] andTable 1 The primers pair sequences for MSP of RB1 and CDH1





bp, base pair.CDH1 [19], either methylated or modified unmethylated
DNA. For PCR amplification, 4 μL of treated DNA was
added to a 50-μL final volume of reaction mixture con-
taining 1 X PCR buffer, dNTPs (1.25 mM each), primers
(300 ng each per reaction), 1.5 mM MgCl2, and 1.25
units of Taq polymerase. Both amplifications were per-
formed in a thermocycler. The protocol for the RB1 ana-
lysis was as follows: 5 minutes of initial denaturing at
96°C; 35 cycles at 95°C, at 55°C and at 72°C for 1 minute
at each temperature; followed by a final elongation step
at 72°C for 7 minutes. The PCR protocol for CDH1
analysis was performed as for HPV detection, as de-
tailed previously. The primer pairs for MSP are shown
in Table 1.
Detection
The amplified PCR products were detected by 10% poly-
acrylamide gel stained with silver nitrate. The approxi-
mate amplified fragment sizes were visualized using the
100 Base Pair Ladder molecular weight marker (Pharmacia
Biotech, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Soft-
ware (GraphPad Software, Inc, USA). Fisher’s exact test
was utilized, and the differences were considered to be
statistically significant when the two-tailed P value < 0.05
(Confidence Interval = 95%).
Results
HPV and EBV detection
HPV DNA was detected in 26.6% (4/15) of control sam-
ples, while among the case samples, this frequency was
66.0% (33/50), specifically 64.4% (11/17) of LSIL cases,
53.3% (8/15) of HSIL cases and 77.8% (14/18) of cervical
cancer samples. A significant association was observed
concerning the presence of HPV and cervical cancer
(p = 0.005). EBV DNA was found in 53.3% (8/15) of
control group samples, 76.4% (13/17) of LSIL cases,
46.7% (7/15) of HSIL cases and 61.1% (11/18) of cer-
vical cancer samples. However, the association between
EBV infection and cervical cancer was not statistically
significant (p = 0.732). Viral co-infection was found in
all groups, with the lowest frequency in the control
group (13.3%) and the highest in cancer cases (55.5%).and the amplicon sizes
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cant association was found (p = 0.027). No virus infec-
tion was detected in one-third of the control samples
(5/15), although in the case groups, this frequency was
lower: 5.8% (1/17) in LSIL, 26.6% (4/15) in HSIL and
16.6% (3/18) in cancer samples. These results are sum-
marized in Table 2.
RB1 and CDH1 methylation
The data concerning the promoter methylation status of
RB1 and CDH1 are shown in Figure 1. The methylation
status of both genes increased with disease progression,
showing the lowest frequencies in the control (6.7% for
RB1 and 13.3% for CDH1) and LSIL samples (5.8% for
RB1 and 11.8% for CDH1) and the highest in cervical
cancer samples (50.0% for RB1 and 33.3% for CDH1).
For RB1, its methylated status was strongly associated
with cancer (p = 0.009). However, CDH1 methylation
was not shown to be associated with this cancer (p =
0.241). Controls and LSIL samples did not show co-
methylation, while both genes were methylated in 27.8%
of cancer samples (5/18). Otherwise, the unmethylated
status decreased in frequency with disorder develop-
ment, as 66.7% (10/15) of the control group and 33.3%
(6/18) of cancer cases presented an unmethylated status
in both genes. That decrease was not quite statistically
significant (p = 0.084).
Correlation between RB1/CDH1 methylation status and
HPV/EBV infection
In the presence of HPV, an increased methylation status
of RB1 was seen with developing pathological changes
(up to 50.0%). In comparing LSIL and cancer samples,
this condition was significantly associated with HPV in-
fection (p = 0.042). The methylation status of CDH1 in-
creased in the presence of EBV (up to 45.5%); however,
the difference was not statistically significant (p = 0.181).
For the RB1 methylation status, only cancer samples
presented methylation in the presence of HPV and EBV
(60.0%). For both genes, the global rate of methylation
was higher when the virus was present: 32.4% for RB1 inTable 2 Presence of HPV and EBV DNA in control, LSIL, HSIL a
Control/Lesion
Type
HPV and EBV detection
HPV, n (%)* EBV, n (% )** HPV
Control (n = 15) 4 (26.6) 8 (53.3) 2 (13
LSIL (n = 17) 11 (64.7) 13 (76.4) 8 (47
HSIL (n = 15) 8 (53.3) 7 (46.7) 4 (26
Cancer (n = 18) 14 (77.8) 11 (61.1) 10 (5
Total (n = 65) 37 (56.9) 39 (60.0) 24 (3
*p = 0.005 (Control versus Cancer).
**p = 0.732 (Control versus Cancer).
***p = 0.027 (Control versus Cancer).
LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepthe presence of HPV vs. 15.3% without virus detection,
and 25.0% for CDH1 with HPV and EBV infection vs.
15.3% with no infection. These results are summarized
in Table 3.
Discussion
The presence of abnormal DNA methylation may rep-
resent a tool for detecting potential biomarkers with
important roles in cervical carcinogenesis. Furthermore,
HPV/EBV infection should improve these findings
because it is correlated with worse clinical presenta-
tion [20].
In a systematic review of the literature, Wentzensen
et al. (2009) [20] reported that CDH1 was one of the
most analyzed genes for methylation in cervical cancer.
Nevertheless, a largely variable methylation frequency
for both cancer and normal tissue was found among the
studies. Feng et al. (2005) [21] reported the relevance
of methylation in pre-cancerous lesions. Our study in-
vestigated the frequency of RB1 and CDH1 methyla-
tion in samples presenting all cervical carcinogenesis
lesion stages and in normal tissue, in addition to
reporting the correlation between this molecular event
and HPV infection.
We detected HPV with a higher frequency among the
case samples (66.0%) than the control (26.6%) in which
77.8% of the cancer group samples presented HPV. We
found a very statistically significant association between
HPV infection and cervical cancer (p = 0.005), as corrob-
orated by the literature. In spite of that proved correl-
ation, this infection alone is probably not sufficient to
develop the disease. On the other hand, the samples in
which HPV was not detected also presented cervical le-
sions. This molecular event was explained by Han et al.
(2006) [22] and Sotlar et al. (2004) [23]. These studies
show the existence of a gene deletion process in region
L1 of HPV. This deletion occurs when HPV DNA inte-
grates into the epithelial regions, and it has been de-
scribed that it occurs in approximately 30% of the cases
of positive cervical cancer samples. As the L1 region is
the target of the primers applied in the current methodnd cervical cancer samples
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Figure 1 RB1 and CDH1 promoter methylation status. LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous
intraepithelial lesions.
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cer cases could be explained by its deletion. Additionally,
studies [24-28] about the Brazilian prevalence of HPV
show that it is lower than in data from Walboomers
et al. (1999) [29], which may be explained by the occur-
rence of the integration events affecting L1 sequences
EBV infection was found in a series of cases and con-
trol groups in which the rate of detection frequency was
not considered statistically significant (p = 0.732). This
finding indicates that EBV cannot be responsible for cer-
vical cancer progression alone. Nevertheless, cancer was
revealed to be associated with HPV and EBV coinfection
(p = 0.027), showing its possible role as a cofactor in cer-
vical cancer progression. Some preliminary studies found
similar results (Nichols et al., 2011 [30]; Ekalaksananan
et. al, 2011 [31]), indicating an association between co-
infection with these viruses and cervical cancer progres-
sion. In a recent study, Khenchouche et al. (2013) [32]
also highlighted the importance of this co-infection for
cervical cancer progression, adding that it could be con-
sidered as a bad prognosis for this type of cancer.
In our study, the methylation status of both genes,
RB1 and CDH1, increased with the severity of the cer-
vical lesion, suggesting that the frequency of methylation
was higher in cancers (50.0% for RB1 and 33.3%
for CDH1) than in the other lesions and controls (6.7%
for RB1 and 13.3% for CDH1 in controls). These dataTable 3 Comparison between RB1/CDH1 methylation and HPV













Control (n = 15) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0)
LSIL (n = 17) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
HSIL (n = 15) 4 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cancer (n = 18) 7 (50.0) 7 (63.6) 6 (60.0) 1 (33.3)
Total (n = 65) 12 (32.4) 7 (17.9) 6 (25.0) 2 (15.3)
*p = 0.0421 (LSIL versus Cancer).
**p = 0.1819 (LSIL versus Cancer).
+, presence; -, absence; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-for CDH1 are consistent with findings in the literature
(Chen et al., 2003 [33]; Dong et al., 2001 [34]; Narayan
et al., 2003 [35]; Attaleb et al., 2009 [36]), which showed
that CDH1 was methylated in less than 50% of cervical
cancer samples, indicating that partial promoter methy-
lation of the CDH1 can down-regulate the gene expres-
sion. Despite this, our data revealed that the association
between CDH1 methylation and cancer was not signifi-
cant (p = 0.241). Few studies have addressed RB1 methy-
lation and its correlation with cervical carcinogenesis,
and this issue needs to be further investigated. However,
our results showed an expressive correlation between
RB1 methylation and cancer samples (p = 0.009). It
might be potentially used as a valuable marker for tumor
diagnosis.
Only HSIL and the cancer group presented methylation
in both genes simultaneously (13.3% and 27.8%, respect-
ively), and these groups had the lowest frequencies for the
unmethylated status in both genes (53.3% and 33.3%, re-
spectively). Our findings also agree with those of Narayan
et al. (2003) [35], who analyzed the methylation status of a
group of genes in cervical carcinogenesis, including RB1
and CDH1, and concluded that global promoter methyla-
tion was higher in more advanced stages of the disease.
However, they did not find promoter methylation in the
RB1 gene. Our results indicate that these differences may










1 (25.0) 0 (0.0) 0 (0.0) 1 (20.0)
0 (0.0) 2 (15.3) 0 (0.0) 0 (0.0)
4 (50.0) 2 (28.6) 2 (50.0) 0 (0.0)
4 (28.6) 5 (45.5) 4 (40.0) 1 (33.3)
9 (24.3) 9 (23.1) 6 (25.0) 2 (15.3)
grade squamous intraepithelial lesions.
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RB1/CDH1 methylation status and HPV/EBV infection.
Our findings showed an important increase in the
methylation status of both genes, RB1 and CDH1, with a
pathological change seen with HPV/EBV infection. It is
important to note that the methylated status of RB1 was
considered to be associated with HPV infection (p = 0.042),
revealing an important role for HPV in cervical cancer
epigenetics.
The elucidation of the molecular relationships between
viral and host proteins and their epigenetic modifica-
tions could improve the process of cervical cancer
screening. Indeed, the detection of possible biomarkers
and cofactors for the possibility of cervical cancer could
allow for molecular differentiation between initial and
precursor lesions.
Conclusions
In conclusion, our results showed that the methylation
status of both genes increased with disease progression,
revealing a significant correlation between RB1 methyla-
tion and cervical cancer. With EBV, the methylation of
RB1 was a tumor-associated event, where only the can-
cer group presented RB1 methylation in the presence of
this virus. HPV infection and cancer progression were
significantly associated. The global frequency of methy-
lation was higher when HPV was present, showing its
important role in this epigenetic mechanism in cervical
carcinogenesis. Nevertheless, EBV seems to have a co-
factor role in this process, which needs to be further
investigated.
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